Medina, Alejandro http://orcid.org/0000-0001-5609-2969
Puig, Noemi
Flores-Montero, Juan http://orcid.org/0000-0002-1119-4387
Jimenez, Cristina
Sarasquete, M.-Eugenia http://orcid.org/0000-0001-7335-3657
Garcia-Alvarez, María
Prieto-Conde, Isabel
Chillon, Carmen
Alcoceba, Miguel
Gutierrez, Norma C.
Oriol, Albert
Rosinol, Laura
Bladè, Joan
Gironella, Mercedes
Hernandez, Miguel T.
Gonzalez-Calle, Veronica
Cedena, Maria-Teresa
Paiva, Bruno http://orcid.org/0000-0003-1977-3815
San-Miguel, Jesus F. http://orcid.org/0000-0002-9183-4857
Lahuerta, Juan-Jose http://orcid.org/0000-0002-3393-9570
Mateos, Maria-Victoria http://orcid.org/0000-0003-2390-1218
Martinez-Lopez, Joaquin http://orcid.org/0000-0001-7908-0063
Orfao, Alberto
Gonzalez, Marcos
Garcia-Sanz, Ramon http://orcid.org/0000-0003-4120-2787
Funding for this research was provided by:
Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (FI19/00320, CPII18/00028)
Fundación Española de Hematología y Hemoterapia
Article History
Received: 23 July 2020
Revised: 14 September 2020
Accepted: 2 October 2020
First Online: 30 October 2020
Conflict of interest
: The authors report grants PI15/01956, CIBERONC-CB16/12/00233, CEI-2010-1-0010, FEHH, FI19/00320, IMS Young Investigator Award 2019, CPII18/00028 and CB16/12/00400 during the conduct of the study. All Spanish funding is co-sponsored by the European Union FEDER program. N.P. has consulted for and has received honoraria from Janssen, Takeda, Amgen and Celgene. A.O. has consulted or served in an advisory role for Amgen, Celgene, Takeda and Janssen. L.R. has received honoraria from Celgene and Janssen. J.B. has received honoraria from Janssen. B.P. has received honoraria, consulted or served in an advisory role for Amgen, Bristol-Myers Squibb, Celgene, EngMab, Janssen, Merck, Novartis, Roche, Sanofi and Takeda. J.F.S.M. has consulted or served in an advisory role for Janssen, Celgene, Takeda, Amgen, BMS, MSD, Novartis, Sanofi, and Roche. J.-J.L. has received honoraria from Amgen, Celgen, and Janssen. M.-V.M. is on the board of directors or an advisory committee and has received honoraria from Janssen, Celgene, Takeda, Amgen, and BMS. J.M.-L. has consulted or served in an advisory role for BMS, Janssen, and Novartis. R.G.-S. has consulted for and received honoraria from Janssen, Takeda, BMS, Hospira, Pharmacyclics, Gilead, and Incyte. The remaining authors declare no conflict of interest.